UBS Group
NBIX icon

UBS Group’s Neurocrine Biosciences NBIX Stock Holding History

UBS Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,400
Closed -$1.56M – 10721
2025
Q2 		$1.56M Buy
+12,400
New +$1.42M ﹤0.01% 5057
2020
Q2 		– Sell
-40,000
Closed -$3.46M – 8208
2020
Q1 		$3.46M Buy
+40,000
New +$3.91M ﹤0.01% 2253
2019
Q3 		– Sell
-27,400
Closed -$2.31M – 8156
2019
Q2 		$2.31M Sell
27,400
-700
-2% -$57.5K ﹤0.01% 3021
2019
Q1 		$2.48M Buy
+28,100
New +$2.35M ﹤0.01% 2813
2016
Q1 		– Sell
-100
Closed -$6K – 7976
2015
Q4 		$6K Hold
100
– – ﹤0.01% 7614
2015
Q3 		$4K Sell
100
-123,800
-100% -$5.98M ﹤0.01% 7829
2015
Q2 		$5.92M Buy
123,900
+41,300
+50% +$1.75M ﹤0.01% 1899
2015
Q1 		$3.28M Sell
82,600
-157,600
-66% -$5.64M ﹤0.01% 2456
2014
Q4 		$5.37M Buy
+240,200
New +$4.55M ﹤0.01% 2031

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's NBIX Position: Q2 2026 in Review

UBS Group reduced its Neurocrine Biosciences (NBIX) stake by 55% in Q2 2026, selling an estimated $100M and leaving 545,937 shares worth $92M. The position accounts for 0.01% of the portfolio, ranked #1184.

UBS Group first reported a position in NBIX in Q4 2014 and has held it in 47 quarters since. The position peaked at $161M in Q1 2026. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • UBS Group held 545,937 shares of Neurocrine Biosciences worth $92M as of Q2 2026.
  • UBS Group sold 675,099 Neurocrine Biosciences shares in Q2 2026, an estimated $100M.
  • Neurocrine Biosciences made up 0.01% of UBS Group's portfolio in Q2 2026, its #1184 holding.
  • UBS Group first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Neurocrine Biosciences position peaked at $161M in Q1 2026.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.